Evidence map›Paper›PMID 31460100›Full record

ArticleACS omega2019

Poly(ethylene glycol)-Based Peptidomimetic "PEGtide" of Oligo-Arginine Allows for Efficient siRNA Transfection and Gene Inhibition.

Alan Hibbitts, Aoife M O'Connor, Joanna McCarthy, Éanna B Forde, Gary Hessman, Caitriona M O'Driscoll, Sally-Ann Cryan, Marc Devocelle

Abstract read
In one paragraph

Article in ACS omega, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Poly(ethylene Glycol)-Based Peptidomimetics (Pegtides) of Antimicrobial Peptides.Chembiochem : a European journal of chemical biology · 2025
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alan HibbittsTissue Engineering Research Group, Department of Anatomy, Department of Chemistry, and Drug Delivery & Advanced Materials Team, School of Pharmacy, Royal College of Surgeons in Ireland (RCSI), 123 St. Stephen's Green, Dublin 2, Ireland.
Aoife M O'ConnorTissue Engineering Research Group, Department of Anatomy, Department of Chemistry, and Drug Delivery & Advanced Materials Team, School of Pharmacy, Royal College of Surgeons in Ireland (RCSI), 123 St. Stephen's Green, Dublin 2, Ireland.
Joanna McCarthyPharmacodelivery Group, School of Pharmacy, University College Cork, Cavanagh Pharmacy Building, College Road, Cork T12 YN60, Ireland.
Éanna B FordeTissue Engineering Research Group, Department of Anatomy, Department of Chemistry, and Drug Delivery & Advanced Materials Team, School of Pharmacy, Royal College of Surgeons in Ireland (RCSI), 123 St. Stephen's Green, Dublin 2, Ireland.
Gary HessmanTrinity Centre for Biomedical Engineering and School of Chemistry, Trinity College Dublin (TCD), The University of Dublin, College Green, Dublin 2, Ireland.
Caitriona M O'DriscollPharmacodelivery Group, School of Pharmacy, University College Cork, Cavanagh Pharmacy Building, College Road, Cork T12 YN60, Ireland.
Sally-Ann CryanTissue Engineering Research Group, Department of Anatomy, Department of Chemistry, and Drug Delivery & Advanced Materials Team, School of Pharmacy, Royal College of Surgeons in Ireland (RCSI), 123 St. Stephen's Green, Dublin 2, Ireland.
Marc DevocelleTissue Engineering Research Group, Department of Anatomy, Department of Chemistry, and Drug Delivery & Advanced Materials Team, School of Pharmacy, Royal College of Surgeons in Ireland (RCSI), 123 St. Stephen's Green, Dublin 2, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While a wide range of experimental and commercial transfection reagents are currently available, persistent problems remain regarding their suitability for continued development. These include the transfection efficiency for difficult-to-transfect cell types and the risks of decreased cell viability that may arise from any transfection that does occur. Therefore, research is now turning toward alternative molecules that improve the toxicity profile of the gene delivery vector (GDV), while maintaining the transfection efficiency. Among them, cell-penetrating peptides, such as octa-arginine, have shown significant potential as GDVs. Their pharmacokinetic and pharmacodynamic properties can be enhanced through peptidomimetic conversion, whereby a peptide is modified into a synthetic analogue that mimics its structure and/or function, but whose backbone is not solely based on α-amino acids. Using this technology, novel peptidomimetics were developed by co- and postpolymerization functionalization of substituted ethylene oxides, producing poly(ethylene glycol) (PEG)-based peptidomimetics termed "PEGtides". Specifically, a PEGtide of the poly(α-amino acid) oligo-arginine [poly(glycidylguanidine)] was assessed for its ability to complex and deliver a small interfering ribonucleic acid (siRNA) using a range of cell assays and high-content analysis. PEGtide-siRNA demonstrated significantly increased internalization and gene inhibition over 24 h in Calu-3 pulmonary epithelial cells compared to commercial controls and octa-arginine-treated samples, with no evidence of toxicity. Furthermore, PEGtide-siRNA nanocomplexes can provide significant levels of gene inhibition in "difficult-to-transfect" mouse embryonic hypothalamic (mHypo N41) cells. Overall, the usefulness of this novel PEGtide for gene delivery was clearly demonstrated, establishing it as a promising candidate for continued translational research.

Identifiers

PMID31460100
PMCPMC6647993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.